RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

One more thought. I have no ill wishes towards Vanda shareholders (I continue to intensely dislike their management, persuasive though they must have been). But this decision annoys the hell out of me. The FDA put tons of time into reviewing this mediocre me-too, and now Vanda will spend a lot of money marketing it, or will get someone else to. All of which are resources wasted--and in this case, maybe $100 million at least will get immolated in 'Fanapt's launch. And the label-expansion studies, and the extended release variations. $200 million?

When I think of the many small companies dying on the vine for lack of a few million, Cortex being only one of them, it's nauseating. What a waste.

But that's just my opinion.

NeuroInvestment